The current vaccine for tuberculosis uses a bovine version of the disease to protect humans who've contracted the illness. It provides some protection but is not entirely effective. However, researchers from the National Heart and Lung Institute at Imperial College London say they've identified a protein that elicits a stronger immune response in those with TB. The protein, called EspC, could be used to provide more better immunity than the currently available vaccine. Report